Novo Nordisk A/S (Nasdaq Copenhagen: Novo-B; NYSE: NVO) has disclosed that Martin Holst Lange, its Executive Vice President of Research & Development and Chief Scientific Officer, sold 12,000 Class B shares on 4 November 2026 at a price of DKK 285.00 per share, generating aggregate proceeds of DKK 3,420,000. The transaction was reported to Novo Nordisk under Article 19 of EU Market Abuse Regulation No. 596/2014, which requires persons discharging managerial responsibilities to disclose their personal trading in company securities. Lange granted Novo Nordisk power of attorney to publish the notification on his behalf, in line with standard regulatory practice for PDMR disclosures.

Key Points

  • Novo Nordisk A/S (Nasdaq Copenhagen: Novo-B; NYSE: NVO), reference 0QIU
  • Chief Scientific Officer Martin Holst Lange sold 12,000 Novo Nordisk B shares on 4 November 2026
  • Transaction executed at DKK 285.00 per share; total aggregated value DKK 3,420,000; venue: Nasdaq Copenhagen
  • Investors may watch for further PDMR activity and any associated regulatory commentary from the company

Martin Holst Lange's Sale of 12,000 Novo Nordisk B Shares at DKK 285.00

The announcement states that the transaction was an outright sale of shares — classified under the financial instrument identification code DK0062498333, which corresponds to Novo Nordisk's Class B ordinary shares listed on Nasdaq Copenhagen. The entire volume of 12,000 shares was transacted at a single price of DKK 285.00, producing a total consideration of DKK 3,420,000. The disclosure is an initial notification, meaning no amendment to an earlier filing has been made. The transaction date is recorded as 4 November 2026, with the company announcement published on 5 November 2026.

Novo Nordisk's EU Market Abuse Regulation Disclosure Obligations

The filing is made pursuant to Article 19 of Regulation (EU) No. 596/2014 on market abuse, which obliges persons holding managerial responsibilities at listed companies — and those closely associated with them — to notify both the company and the relevant competent authority of transactions conducted in the issuer's financial instruments. Novo Nordisk's LEI is recorded in the announcement as 549300DAQ1CVT6CXN342. As Executive Vice President, R&D and Chief Scientific Officer, Lange is classified as a person discharging managerial responsibilities, making this disclosure a mandatory regulatory requirement rather than a voluntary update.

Novo Nordisk's Global Healthcare Operations and Dual-Exchange Listing

Headquartered in Bagsværd, Denmark, Novo Nordisk is a global healthcare company employing over 66,500 people worldwide. The company develops treatments supporting millions of patients, with its B shares traded on Nasdaq Copenhagen and American Depositary Receipts listed on the New York Stock Exchange under the ticker NVO. The company's research-driven model, led in part by the R&D function that Lange oversees as CSO, sits at the core of its long-term commercial strategy, making insider trading disclosures from senior R&D leadership of particular interest to investors monitoring the company's pipeline and leadership confidence signals.